Rheumatic manifestations of systemic diseases (hemochromatosis, Wilson

14T131: Cardiovascular Rheumatology: Lessons Learned from Targeting Inflammation to Modulate CV Risk

Speaker(s)

• 

  Ian Bruce, MD

  Professor
  University of Manchester
  Manchester, United Kingdom

  Disclosure(s): AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Aurinia: Consultant (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); UCB: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 31, 2020)
• JF

  Johan Frostegard, MD, PhD

  Karolinska Institutet
  Stockholm, Sweden

  Disclosure(s): No financial relationships with ineligible companies to disclose
• SM

  Susan Manzi, MD, MPH

  Allegheny Health Network
  Pittsburgh, PA, United States

  Disclosure(s): AbbVie: Grant/Research Support (Ongoing); Allegheny Singer Research Institute: Intellectual Property/Patents (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Exagen Diagnostics, Inc: Consultant (Ongoing), Intellectual Property/Patents (Ongoing), Royalties (Ongoing); GSK: Consultant (Ongoing), Grant/Research Support (Ongoing); Lilly: Consultant (Ongoing); Lupus Foundation of America: Officer or Board Member (Ongoing); Novartis: Consultant (Ongoing); UCB Advisory Board: Consultant (Ongoing); Univiersity of Pittsburgh: Intellectual Property/Patents (Ongoing)

Understanding the role of inflammation in premature CVD in systemic autoimmune diseases; modulation of the CVD risk by targeting inflammation; and evidence of treating CVD by targeting inflammation in the non-autoimmune population.

Presentations:

• 12:00 PM – 12:15 PM PT

  Cardiovascular Rheumatology: Lessons Learned From Targeting Inflammation to Modulate CV Risk
  

  Speaker: Susan Manzi, MD, MPH – Allegheny Health Network
• 12:15 PM – 12:30 PM PT

  Immune-Based Pathogenesis of Atherosclerosis
  

  Speaker: Johan Frostegard, MD, PhD – Karolinska Institutet
• 12:30 PM – 12:45 PM PT

  Treating Inflammation to Improve CVD Outcomes in Non-autoimmune Populations
  

  Speaker: Ian N. Bruce, MD – University of Manchester
• 12:45 PM – 1:00 PM PT

  Q&A